Raymond James Financial
CAPR icon

Raymond James Financial’s Capricor Therapeutics CAPR Stock Holding History

Raymond James Financial’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.9M Buy
200,148
+3,292
+2% +$36.5K ﹤0.01% 3537
2026
Q2 		$4.74M Buy
196,856
+556
+0.3% +$16.9K ﹤0.01% 2773
2026
Q1 		$5.97M Buy
196,300
+910
+0.5% +$24.2K ﹤0.01% 2454
2025
Q4 		$5.64M Buy
195,390
+4,098
+2% +$53.5K ﹤0.01% 2424
2025
Q3 		$1.38M Buy
191,292
+180,234
+1,630% +$1.33M ﹤0.01% 3461
2025
Q2 		$110K Sell
11,058
-58
-0.5% -$613 ﹤0.01% 4830
2025
Q1 		$105K Buy
+11,116
New +$154K ﹤0.01% 4539

Other funds holding CAPR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Jump Financial
Jump Financial Chicago, Illinois $13.9B AUM 45.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Raymond James Financial's CAPR Position: Q3 2026 in Review

Raymond James Financial increased its Capricor Therapeutics (CAPR) stake by 1.7% in Q3 2026, buying an estimated $36.5K and bringing the position to 200,148 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3537.

Raymond James Financial first reported a position in CAPR in Q1 2025 and has held it in 7 quarters since. The position peaked at $5.97M in Q1 2026. 106 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Raymond James Financial held 200,148 shares of Capricor Therapeutics worth $1.9M as of Q3 2026.
  • Raymond James Financial bought 3,292 Capricor Therapeutics shares in Q3 2026, an estimated $36.5K.
  • Capricor Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3537 holding.
  • Raymond James Financial first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Raymond James Financial's Capricor Therapeutics position peaked at $5.97M in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.